Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments

Abstract Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of...

Full description

Saved in:
Bibliographic Details
Published in:Briefings in bioinformatics 2022-01, Vol.23 (1)
Main Authors: Tanoli, Ziaurrehman, Aldahdooh, Jehad, Alam, Farhan, Wang, Yinyin, Seemab, Umair, Fratelli, Maddalena, Pavlis, Petr, Hajduch, Marian, Bietrix, Florence, Gribbon, Philip, Zaliani, Andrea, Hall, Matthew D, Shen, Min, Brimacombe, Kyle, Kulesskiy, Evgeny, Saarela, Jani, Wennerberg, Krister, Vähä-Koskela, Markus, Tang, Jing
Format: Article
Language:English
Subjects:
Annotations
Assaying
COVID-19
Data integration
Data processing
Drug screening
Information processing
Internet
Optimization
Problem Solving Protocol
Reagents
Screening
Servers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of Minimal Information for Chemosensitivity Assays (MICHA), accessed via https://micha-protocol.org. Distinguished from existing efforts that are often lacking support from data integration tools, MICHA can automatically extract publicly available information to facilitate the assay annotation including: 1) compounds, 2) samples, 3) reagents and 4) data processing methods. For example, MICHA provides an integrative web server and database to obtain compound annotation including chemical structures, targets and disease indications. In addition, the annotation of cell line samples, assay protocols and literature references can be greatly eased by retrieving manually curated catalogues. Once the annotation is complete, MICHA can export a report that conforms to the FAIR principle (Findable, Accessible, Interoperable and Reusable) of drug screening studies. To consolidate the utility of MICHA, we provide FAIRified protocols from five major cancer drug screening studies as well as six recently conducted COVID-19 studies. With the MICHA web server and database, we envisage a wider adoption of a community-driven effort to improve the open access of drug sensitivity assays.
ISSN:1467-5463
1477-4054
DOI:10.1093/bib/bbab350